Autolus Therapeutics PLC
NASDAQ:AUTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (0.2), the stock would be worth $-0.24 (117% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.3 | $1.42 |
0%
|
| Industry Average | 0.2 | $-0.24 |
-117%
|
| Country Average | 0.1 | $-0.12 |
-108%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
377.9m USD | -1.3 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 18.3 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 18.4 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 15.8 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 29.8 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 15.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 121.3 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 11.8 | 30.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.1 |
| 70th Percentile | 0.2 |
| Max | 2 143.8 |
Other Multiples
Autolus Therapeutics PLC
Glance View
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.
